Cancer based pharmacogenomics network supported with scientific evidences: From the view of drug repurposing

Liwei Wang, Hongfang D Liu, Christopher G. Chute, Qian Zhu

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Pharmacogenomics (PGx) as an emerging field, is poised to change the way we practice medicine and deliver health care by customizing drug therapies on the basis of each patient's genetic makeup. A large volume of PGx data including information among drugs, genes, and single nucleotide polymorphisms (SNPs) has been accumulated. Normalized and integrated PGx information could facilitate revelation of hidden relationships among drug treatments, genomic variations, and phenotype traits to better support drug discovery and next generation of treatment. Methods: In this study, we generated a normalized and scientific evidence supported cancer based PGx network (CPN) by integrating cancer related PGx information from multiple well-known PGx resources including the Pharmacogenomics Knowledge Base (PharmGKB), the FDA PGx Biomarkers in Drug Labeling, and the Catalog of Published Genome-Wide Association Studies (GWAS). We successfully demonstrated the capability of the CPN for drug repurposing by conducting two case studies. Conclusions: The CPN established in this study offers comprehensive cancer based PGx information to support cancer orientated research, especially for drug repurposing.

Original languageEnglish (US)
Article number042
JournalBioData Mining
Volume8
Issue number1
DOIs
StatePublished - Jan 8 2015

Fingerprint

Drug Repositioning
Drug therapy
Pharmacogenetics
Cancer
Drugs
Genes
Biomarkers
Nucleotides
Polymorphism
Health care
Pharmaceutical Preparations
Labeling
Medicine
Neoplasms
Drug Catalogs
Drug Labeling
Drug Discovery
Knowledge Bases
Single nucleotide Polymorphism
Genome-Wide Association Study

Keywords

  • Cancer
  • Drug repurposing
  • Network
  • Pharmacogenomics

ASJC Scopus subject areas

  • Genetics
  • Biochemistry
  • Molecular Biology
  • Computer Science Applications
  • Computational Theory and Mathematics
  • Computational Mathematics

Cite this

Cancer based pharmacogenomics network supported with scientific evidences : From the view of drug repurposing. / Wang, Liwei; Liu, Hongfang D; Chute, Christopher G.; Zhu, Qian.

In: BioData Mining, Vol. 8, No. 1, 042, 08.01.2015.

Research output: Contribution to journalArticle

@article{b67a8557d265450dab0c23395c80e071,
title = "Cancer based pharmacogenomics network supported with scientific evidences: From the view of drug repurposing",
abstract = "Background: Pharmacogenomics (PGx) as an emerging field, is poised to change the way we practice medicine and deliver health care by customizing drug therapies on the basis of each patient's genetic makeup. A large volume of PGx data including information among drugs, genes, and single nucleotide polymorphisms (SNPs) has been accumulated. Normalized and integrated PGx information could facilitate revelation of hidden relationships among drug treatments, genomic variations, and phenotype traits to better support drug discovery and next generation of treatment. Methods: In this study, we generated a normalized and scientific evidence supported cancer based PGx network (CPN) by integrating cancer related PGx information from multiple well-known PGx resources including the Pharmacogenomics Knowledge Base (PharmGKB), the FDA PGx Biomarkers in Drug Labeling, and the Catalog of Published Genome-Wide Association Studies (GWAS). We successfully demonstrated the capability of the CPN for drug repurposing by conducting two case studies. Conclusions: The CPN established in this study offers comprehensive cancer based PGx information to support cancer orientated research, especially for drug repurposing.",
keywords = "Cancer, Drug repurposing, Network, Pharmacogenomics",
author = "Liwei Wang and Liu, {Hongfang D} and Chute, {Christopher G.} and Qian Zhu",
year = "2015",
month = "1",
day = "8",
doi = "10.1186/s13040-015-0042-8",
language = "English (US)",
volume = "8",
journal = "BioData Mining",
issn = "1756-0381",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Cancer based pharmacogenomics network supported with scientific evidences

T2 - From the view of drug repurposing

AU - Wang, Liwei

AU - Liu, Hongfang D

AU - Chute, Christopher G.

AU - Zhu, Qian

PY - 2015/1/8

Y1 - 2015/1/8

N2 - Background: Pharmacogenomics (PGx) as an emerging field, is poised to change the way we practice medicine and deliver health care by customizing drug therapies on the basis of each patient's genetic makeup. A large volume of PGx data including information among drugs, genes, and single nucleotide polymorphisms (SNPs) has been accumulated. Normalized and integrated PGx information could facilitate revelation of hidden relationships among drug treatments, genomic variations, and phenotype traits to better support drug discovery and next generation of treatment. Methods: In this study, we generated a normalized and scientific evidence supported cancer based PGx network (CPN) by integrating cancer related PGx information from multiple well-known PGx resources including the Pharmacogenomics Knowledge Base (PharmGKB), the FDA PGx Biomarkers in Drug Labeling, and the Catalog of Published Genome-Wide Association Studies (GWAS). We successfully demonstrated the capability of the CPN for drug repurposing by conducting two case studies. Conclusions: The CPN established in this study offers comprehensive cancer based PGx information to support cancer orientated research, especially for drug repurposing.

AB - Background: Pharmacogenomics (PGx) as an emerging field, is poised to change the way we practice medicine and deliver health care by customizing drug therapies on the basis of each patient's genetic makeup. A large volume of PGx data including information among drugs, genes, and single nucleotide polymorphisms (SNPs) has been accumulated. Normalized and integrated PGx information could facilitate revelation of hidden relationships among drug treatments, genomic variations, and phenotype traits to better support drug discovery and next generation of treatment. Methods: In this study, we generated a normalized and scientific evidence supported cancer based PGx network (CPN) by integrating cancer related PGx information from multiple well-known PGx resources including the Pharmacogenomics Knowledge Base (PharmGKB), the FDA PGx Biomarkers in Drug Labeling, and the Catalog of Published Genome-Wide Association Studies (GWAS). We successfully demonstrated the capability of the CPN for drug repurposing by conducting two case studies. Conclusions: The CPN established in this study offers comprehensive cancer based PGx information to support cancer orientated research, especially for drug repurposing.

KW - Cancer

KW - Drug repurposing

KW - Network

KW - Pharmacogenomics

UR - http://www.scopus.com/inward/record.url?scp=84924043749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924043749&partnerID=8YFLogxK

U2 - 10.1186/s13040-015-0042-8

DO - 10.1186/s13040-015-0042-8

M3 - Article

AN - SCOPUS:84924043749

VL - 8

JO - BioData Mining

JF - BioData Mining

SN - 1756-0381

IS - 1

M1 - 042

ER -